MedTrace Logo

855303-RNA Biomarker Validation

NCT06872775 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2026-01-16

No results posted yet for this study

Summary

The purpose of this study is to test the accuracy of using RNA in blood as a way to forecast new fracture healing outcome.

Conditions

  • Fractures, Bone

Interventions

OTHER

Blood draws to assess RNA expression levels

None. Standard of Care (SOC) only.

Sponsors & Collaborators

  • PharPoint Research, Inc.

    collaborator INDUSTRY

  • Children's Hospital of Philadelphia

    collaborator OTHER

  • Cooperative Human Tissue Network - Eastern Division (CHTN-ED)

    collaborator UNKNOWN

  • Osetomics, LLC

    collaborator UNKNOWN

  • Resonant Clinical/Therapak, Claremont, California

    collaborator UNKNOWN

  • ResearchDx, Irvine, CA

    collaborator UNKNOWN

  • University of Pennsylvania

    lead OTHER

Principal Investigators

  • Samir Mehta, MD · University of Pennsylvania

  • Annamarie D Horan, MPA, PhD · University of Pennsylvania

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-25
Primary Completion
2028-08-24
Completion
2028-08-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06872775 on ClinicalTrials.gov